Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

5.870 -0.630 (-9.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atara Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Why Is Assertio (ASRT) Stock Down 39% Today? ↗
Assertio stock is dropping on Thursday as investors in ASRT react to the company's poor earnings results for the third quarter of 2023. 
Via InvestorPlace
News headline image
Why Is Atara Biotherapeutics (ATRA) Stock Down 50% Today? ↗
Atara Biotherapeutics stock is falling on Thursday as investors in ATRA react to the company's latest Phase 2 clinical trial data. 
Via InvestorPlace
News headline image
Why Atara Biotherapeutics Shares Are Plummeting Today ↗
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) shares are trading lower after the company said that primary analysis data from its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping tabs on for Thursday morning! 
Via InvestorPlace
News headline image
Atara Biotherapeutics's Earnings Outlook ↗
 
Via Benzinga
News headline image
Atara Biotherapeutics Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
A Preview Of Atara Biotherapeutics's Earnings ↗
 
Via Benzinga
News headline image
Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Why Gorilla Technology Group Shares Are Trading Lower By 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 104.5% to $0.1916. 
Via Benzinga
News headline image
Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
3 Doomed Biotech Stocks Destined for Disaster ↗
Doomed biotech stocks are a major part of the natural cycle within the sector that results in a lot of failures. 
Via InvestorPlace
News headline image
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease. 
Via Benzinga
News headline image
Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.